Ekso Bionics Q2 Revenue Hits $7.9M, Assets Top $141M

TL;DR

Ekso Bionics Q2 revenue $7.9M, assets $141.4M, liabilities $18.4M. Solid quarter.

AI Summary

Ekso Bionics Holdings, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $141,429,000 and total liabilities of $18,444,000 as of June 30, 2024. For the three months ended June 30, 2024, the company reported revenue of $7.9 million.

Why It Matters

This filing provides a snapshot of Ekso Bionics' financial health and operational performance for the second quarter of 2024, impacting investor confidence and strategic decisions.

Risk Assessment

Risk Level: medium — The company's financial performance and market position present inherent risks typical for a growth-stage medical device company.

Key Numbers

• $141.4M — Total Assets (As of June 30, 2024)
• $18.4M — Total Liabilities (As of June 30, 2024)
• $7.9M — Q2 2024 Revenue (For the three months ended June 30, 2024)

Key Players & Entities

• EKSO BIONICS HOLDINGS, INC. (company) — Filer
• 20240630 (date) — Reporting period end date
• $141,429,000 (dollar_amount) — Total assets as of June 30, 2024
• $18,444,000 (dollar_amount) — Total liabilities as of June 30, 2024
• $7.9 million (dollar_amount) — Revenue for the three months ended June 30, 2024

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share EKSO Nasdaq Cap
• $100 — posit insurance limits of approximately $100 at each of the Company's two foreign ba
• $250 — nstitutions with each balance under the $250 Federal Deposit Insurance Corporation (

Filing Documents

• ekso20240630_10q.htm (10-Q) — 1651KB
• ex_676558.htm (EX-31.1) — 13KB
• ex_676559.htm (EX-31.2) — 13KB
• ex_676560.htm (EX-32.1) — 6KB
• ex_676561.htm (EX-32.2) — 6KB
• 0001437749-24-023765.txt ( ) — 8204KB
• ekso-20240630.xsd (EX-101.SCH) — 68KB
• ekso-20240630_cal.xml (EX-101.CAL) — 39KB
• ekso-20240630_def.xml (EX-101.DEF) — 451KB
• ekso-20240630_lab.xml (EX-101.LAB) — 395KB
• ekso-20240630_pre.xml (EX-101.PRE) — 496KB
• ekso20240630_10q_htm.xml (XML) — 1544KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 4 Condensed Consolidated Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023 4 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months ended June 30, 2024 and 2023 (unaudited) 5 Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months ended June 30, 2024 and 2023 (unaudited) 6 Condensed Consolidated Statements of Cash Flows for the Six Months ended June 30, 2024 and 2023 (unaudited) 8 Notes to Condensed Consolidated Financial Statements (unaudited) 9 Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 31 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 40 Item 4.

Controls and Procedures

Controls and Procedures 40

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 41 Item 1A.

Risk Factors

Risk Factors 41 Item 5. Other Information 41 Item 6. Exhibits 42

Signatures

Signatures 43 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Ekso Bionics Holdings, Inc. Condensed Consolidated Balance Sheets (In thousands, except par value) June 30, 2024 December 31, 2023 (unaudited) Assets Current assets: Cash and restricted cash $ 5,885 $ 8,638 Accounts receivable, net of allowances of $ 28 and $ 79 , respectively 6,520 5,645 Inventories 4,974 5,050 Prepaid expenses and other current assets 1,263 875 Total current assets 18,642 20,208 Property and equipment, net 1,748 2,018 Right-of-use assets 989 977 Intangible assets, net 4,739 4,892 Goodwill 431 431 Other assets 435 392 Total assets $ 26,984 $ 28,918 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 2,125 $ 1,847 Accrued liabilities 1,973 2,664 Deferred revenues, current 1,926 1,993 Note payable, current 1,250 1,250 Lease liabilities, current 430 363 Total current liabilities 7,704 8,117 Deferred revenues 2,016 2,169 Notes payable, net 4,352 4,832 Lease liabilities 659 723 Warrant liabilities 49 366 Other non-current liabilities 145 105 Total liabilities 14,925 16,312 Commitments and contingencies (Note 14) Stockholders' equity: Convertible preferred stock, $ 0.001 par value; 10,000 shares authorized; none issued and outstanding at June 30, 2024 and December 31, 2023 — — Common stock, $ 0.001 par value; 141,429 shares authorized; 18,444 and 14,848 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 19 15 Additional paid-in capital 256,491 251,580 Accumulated other comprehensive income 539 156 Accumulated deficit ( 244,990 ) ( 239,145 ) Total stockholders' equity 12,059 12,606 Total liabilities and stockholders' equity $ 26,984 $ 28,918 The accompanying notes are an integral part of these condensed consolidated financial statements 4 Table of Contents Ekso Bionics Holdings, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss

View Full Filing

View this 10-Q filing on SEC EDGAR